StreetInsider.com News Articles

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it

RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

Wed, 15 Jul 2026 08:45:00 -0400

Issued on behalf of Conexeu Sciences Inc.

Marathon Petroleum (MPC) PT Raised to $289 at Barclays

Mon, 13 Jul 2026 03:22:12 -0400

Barclays analyst Theresa Chen raised the price target on Marathon Petroleum (NYSE: MPC) to $289.00 (from $270.00) while maintaining a Overweight rating.

Marathon Petroleum (MPC) PT Raised to $321 at UBS

Fri, 10 Jul 2026 10:13:43 -0400

UBS analyst Manav Gupta raised the price target on Marathon Petroleum (NYSE: MPC) to $321.00 (from $280.00) while maintaining a Buy rating.

The analyst commented, "We are adjusting our 2Q 26 EPS estimate to $14.49 vs. Street of $12.17 and prior UBSe of $10.98. We expect adjusted EBITDA of $6,966M vs. $2,763M in 1Q 26. We are modeling capex of $732M in 2Q 26. We are modeling buybacks of $1,750M in 2Q 26 (MPC could surprise to the upside). Higher refining margins driving positive revisions for 2026 / 2027."

Marathon Petroleum (MPC) PT Raised to $321 at UBS

Fri, 10 Jul 2026 10:13:43 -0400

UBS analyst Manav Gupta raised the price target on Marathon Petroleum (NYSE: MPC) to $321.00 (from $280.00) while maintaining a Buy rating.

Form 8-K Marathon Petroleum Corp For: Jun 26

Mon, 29 Jun 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260629/26703095.html

Form 8-K Marathon Petroleum Corp For: Jun 26

Mon, 29 Jun 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260629/26703095.html

Marathon Petroleum (MPC) PT Lowered to $315 at TD Cowen

Mon, 29 Jun 2026 08:29:08 -0400

TD Cowen analyst Jason Gabelman lowered the price target on Marathon Petroleum (NYSE: MPC) to $315.00 (from $320.00) while maintaining a rating.

Form 11-K Marathon Petroleum Corp For: Dec 31

Thu, 25 Jun 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260625/26687479.html

Form 11-K Marathon Petroleum Corp For: Dec 31

Thu, 25 Jun 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260625/26687479.html

Madison Pacific Properties Inc. (TSX: MPC and MPC.C) announces results of Annual General Meeting

Thu, 18 Jun 2026 18:36:00 -0400

VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Madison Pacific Properties Inc. (the Company), reports the voting results of the Annual General Meeting of its shareholders held June 18, 2026 in Vancouver, British Columbia.

The following seven nominees were elected as directors of the Company by the following votes:

Nominee

The following seven nominees were elected as directors of the Company by the following votes:

Nominee

The following seven nominees were elected as directors of the Company by the following votes:

Nominee